Cure launches first national index on biomedical translation

By AI, Created 10:24 AM UTC, May 20, 2026, /AGP/ – Cure released the first Cure Innovation Index, a new national ranking that measures how effectively U.S. biomedical institutions turn research into therapies, companies and clinical impact. The framework evaluates 303 institutions across all 50 states, Washington, D.C. and Puerto Rico, with the goal of showing which schools and research centers translate science into real-world outcomes best.

Why it matters: - The Cure Innovation Index aims to shift attention from funding, publications and patents to measurable translation of science into healthcare impact. - The platform is designed to help universities, institutes and centers see where they outperform peers and where they need to improve. - The launch comes as federal agencies push harder on commercialization and global competition raises pressure to turn discovery into outcomes.

What happened: - Cure launched the Cure Innovation Index on April 29, 2026. - The Index ranks 303 U.S. biomedical research institutions selected from more than 6,000 nationwide. - The rankings cover all 50 states, the District of Columbia and Puerto Rico. - Cure separated universities from institutes and centers in the 2026 rankings to reflect different structures and missions. - The top five universities were Harvard University, Stanford University, the University of Pennsylvania, the Massachusetts Institute of Technology and the University of California, San Francisco. - The top five institutes and centers were Mass General Brigham, Mayo Clinic, Scripps Research Institute, Memorial Sloan Kettering Cancer Center and Dana–Farber Cancer Institute. - The Index also identified 20 institutions that are “punching above their weight” relative to funding levels. - The top five in that group were Indiana University, Indianapolis; New York Medical College; the University of Maryland, Baltimore County; the University of Memphis; and Rensselaer Polytechnic Institute.

The details: - The Index uses a proprietary methodology built around 25 indicators across three core domains: Research Capabilities, Entrepreneurial Readiness and Market Translation. - Those domains are intended to capture the structural, operational and cultural factors behind successful translation from discovery to therapies, companies and health impact. - The platform adds institution-specific diagnostics, peer benchmarking, gap analysis, insights, strategic recommendations and interactive data visualizations. - Cure says the tool can help institutional leaders make investment and strategy decisions, while also giving faculty and campus entrepreneurs recommendations and resources. - The methodology combines validated data from more than a dozen federal and commercial databases. - Data sources include the Carnegie Classification, ClinicalTrials.gov, the Higher Education Research and Development Survey, the Howard Hughes Medical Institute, the National Academies of Sciences, Engineering, and Medicine, the National Institutes of Health, the National Science Foundation, major scientific awards databases and Dimensions. - The Index also uses original surveys of more than 3,000 researchers and industry leaders. - Institutional audits were used to assess laboratory technologies, technology transfer operations and educational curricula. - The methodology has been described in an article and submitted for publication in a peer-reviewed journal.

Between the lines: - The ranking suggests biomedical success is increasingly judged by what institutions help create, not just what they publish or fund. - Institutions that perform well appear to combine scientific strength with commercialization infrastructure, industry ties and an entrepreneurial culture. - The “punching above their weight” list suggests resource levels alone do not determine translational performance. - Thomas P. Sakmar of The Rockefeller University said scientific excellence alone is not enough and that institutions need infrastructure, partnerships and culture that turn innovation into patient benefit. - Seema Kumar, Cure’s CEO, said the Index is meant to measure translational performance across the ecosystem and reflect its impact on patients, the healthcare system and the broader economy.

What’s next: - Cure will use the Index platform to provide schools and research centers with benchmarking and improvement recommendations. - The company expects the framework to help institutions strengthen their ability to scale healthcare solutions and maintain biomedical innovation leadership. - Cure says the Index methodology will continue to serve as the basis for future analysis and publication.